Targeting oncogenic KRAS in non-small cell lung cancer with EGFR aptamer-conjugated multifunctional RNA nanoparticles

Bos, 1989, ras oncogenes in human cancer: a review, Cancer Res., 49, 4682 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Karnoub, 2008, Ras oncogenes: split personalities, Nat. Rev. Mol. Cell Biol., 9, 517, 10.1038/nrm2438 Lito, 2016, Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism, Science, 351, 604, 10.1126/science.aad6204 Patricelli, 2016, Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State, Cancer Discov., 6, 316, 10.1158/2159-8290.CD-15-1105 Siegel, 2021, Cancer Statistics, 2021, CA A Cancer J. Clin., 71, 7, 10.3322/caac.21654 2013, A genomics-based classification of human lung tumors, Sci. Transl. Med., 5, 209ra153 Dogan, 2012, Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers, Clin. Cancer Res., 18, 6169, 10.1158/1078-0432.CCR-11-3265 El Osta, 2019, Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience, J. Thorac. Oncol., 14, 876, 10.1016/j.jtho.2019.01.020 Scheffler, 2019, K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways, J. Thorac. Oncol., 14, 606, 10.1016/j.jtho.2018.12.013 Linardou, 2008, Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer, Lancet Oncol., 9, 962, 10.1016/S1470-2045(08)70206-7 Mao, 2010, KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies, Lung Cancer, 69, 272, 10.1016/j.lungcan.2009.11.020 Kobayashi, 2005, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, N. Engl. J. Med., 352, 786, 10.1056/NEJMoa044238 Pao, 2004, EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib, Proc. Natl. Acad. Sci. USA, 101, 13306, 10.1073/pnas.0405220101 Jacobs, 2021, Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study, Clin. Cancer Res., 27, 1612, 10.1158/1078-0432.CCR-20-1831 Lièvre, 2006, KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res., 66, 3992, 10.1158/0008-5472.CAN-06-0191 Peeters, 2013, Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab, J. Clin. Oncol., 31, 759, 10.1200/JCO.2012.45.1492 Moore, 2007, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J. Clin. Oncol., 25, 1960, 10.1200/JCO.2006.07.9525 Sklar, 1988, The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation, Science, 239, 645, 10.1126/science.3277276 Duldulao, 2013, Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma, Ann. Surg Oncol., 20, 2166, 10.1245/s10434-013-2910-0 Mak, 2015, Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer, Clin. Lung Cancer, 16, 24, 10.1016/j.cllc.2014.09.005 Wang, 2017, Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway, Cancer Res., 77, 2018, 10.1158/0008-5472.CAN-16-0808 Yang, 2021, Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair, Nucleic Acids Res., 49, 11067, 10.1093/nar/gkab871 Ostrem, 2013, K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions, Nature, 503, 548, 10.1038/nature12796 Janes, 2018, Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor, Cell, 172, 578, 10.1016/j.cell.2018.01.006 Canon, 2019, The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity, Nature, 575, 217, 10.1038/s41586-019-1694-1 Moore, 2020, RAS-targeted therapies: is the undruggable drugged?, Nat. Rev. Drug Discov., 19, 533, 10.1038/s41573-020-0068-6 Guo, 2010, The emerging field of RNA nanotechnology, Nat. Nanotechnol., 5, 833, 10.1038/nnano.2010.231 Jasinski, 2017, Advancement of the Emerging Field of RNA Nanotechnology, ACS Nano, 11, 1142, 10.1021/acsnano.6b05737 Ghimire, 2020, RNA Nanoparticles as Rubber for Compelling Vessel Extravasation to Enhance Tumor Targeting and for Fast Renal Excretion to Reduce Toxicity, ACS Nano, 14, 13180, 10.1021/acsnano.0c04863 Li, 2022, The dynamic, motile and deformative properties of RNA nanoparticles facilitate the third milestone of drug development, Adv. Drug Deliv. Rev., 186, 114316, 10.1016/j.addr.2022.114316 Shu, 2014, Stable RNA nanoparticles as potential new generation drugs for cancer therapy, Adv. Drug Deliv. Rev., 66, 74, 10.1016/j.addr.2013.11.006 Gupta, 2009, Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method, Mod. Pathol., 22, 128, 10.1038/modpathol.2008.182 Shu, 2015, Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology, ACS Nano, 9, 9731, 10.1021/acsnano.5b02471 Fleming, 2005, Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy, Mol. Cancer Res., 3, 413, 10.1158/1541-7786.MCR-04-0206 Pecot, 2014, Therapeutic silencing of KRAS using systemically delivered siRNAs, Mol. Cancer Therapeut., 13, 2876, 10.1158/1535-7163.MCT-14-0074 Yuan, 2014, Development of siRNA payloads to target KRAS-mutant cancer, Cancer Discov., 4, 1182, 10.1158/2159-8290.CD-13-0900 Xue, 2014, Small RNA combination therapy for lung cancer, Proc. Natl. Acad. Sci. USA, 111, E3553, 10.1073/pnas.1412686111 Zorde Khvalevsky, 2013, Mutant KRAS is a druggable target for pancreatic cancer, Proc. Natl. Acad. Sci. USA, 110, 20723, 10.1073/pnas.1314307110 Ross, 2017, Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS, Sci. Transl. Med., 9, eaal5253, 10.1126/scitranslmed.aal5253 Afonin, 2010, In vitro assembly of cubic RNA-based scaffolds designed in silico, Nat. Nanotechnol., 5, 676, 10.1038/nnano.2010.160 Lee, 2012, Self-assembled RNA interference microsponges for efficient siRNA delivery, Nat. Mater., 11, 316, 10.1038/nmat3253 Li, 2021, Non-Small-Cell Lung Cancer Regression by siRNA Delivered Through Exosomes That Display EGFR RNA Aptamer, Nucleic Acid Therapeut., 31, 364, 10.1089/nat.2021.0002 Awad, 2021, Acquired Resistance to KRAS(G12C) Inhibition in Cancer, N. Engl. J. Med., 384, 2382, 10.1056/NEJMoa2105281 Inamura, 2010, Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features?, Arch. Pathol. Lab Med., 134, 66, 10.5858/2008-0586-RAR1.1 Agustoni, 2019, EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis, Cancer Treat Rev., 72, 15, 10.1016/j.ctrv.2018.08.002 DeNicola, 2011, Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis, Nature, 475, 106, 10.1038/nature10189 Pietrantonio, 2017, Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer, Clin. Cancer Res., 23, 2414, 10.1158/1078-0432.CCR-16-1863 Gazdar, 2009, Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors, Oncogene, 28, S24, 10.1038/onc.2009.198 Shu, 2011, Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics, Nat. Nanotechnol., 6, 658, 10.1038/nnano.2011.105 Shu, 2013, Fabrication of 14 different RNA nanoparticles for specific tumor targeting without accumulation in normal organs, RNA, 19, 767, 10.1261/rna.037002.112 Shu, 2013, Fabrication of pRNA nanoparticles to deliver therapeutic RNAs and bioactive compounds into tumor cells, Nat. Protoc., 8, 1635, 10.1038/nprot.2013.097 Sunaga, 2011, Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy, Mol. Cancer Therapeut., 10, 336, 10.1158/1535-7163.MCT-10-0750 Yang, 2020, Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy, Clin. Cancer Res., 26, 3740, 10.1158/1078-0432.CCR-19-3373